On February 11, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) announced that it would buy back 2.5 million shares of the company with a capital of 1 billion yuan in the next 12 months, and the repurchase price would not exceed 400 yuan / share. The repurchased shares would be cancelled and the registered capital would be reduced according to law.
It should be noted that since 2022, it has been difficult for “medical equipment Mao” Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) to survive against the background of the collective decline of big white horses in the whole pharmaceutical sector. On the first trading day of the year, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) plummeted by 10%. After that, it continued to decline in overcast for a week. Although it experienced a short rebound, it began to appear six consecutive overcast at the end of January. From 385.60 yuan / share at the end of December 2021 to 296.25 yuan / share in February 2022, a decrease of 23.17%.
The main reason behind the continuous decline of “instrument Mao” can also be traced back to the rumor that its performance does not meet the standard. Previously, some media reported that the performance of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) did not meet expectations, the performance completion of many branches was less than 50%, and the sales staff of the company resigned in large quantities; At the same time, it may be related to the publication of centralized mining results in Nanjing. In December 2021, Nanjing Medical Insurance Bureau issued an announcement on the implementation of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) with volume price reduction. The stock price has experienced a flash in August 2020.
In August 2021, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) also implemented a repurchase with an amount of 1 billion. At that time, its share price plunged 45% in just two months.
Due to the gradual decline of the secondary market, the shareholders of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) also issued their share reduction plans after the lifting of the ban.
According to the data, on October 18, 2021, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) issued a suggestive announcement on the listing and circulation of shares issued before the initial public offering. The total number of shares lifted was up to 717 million. Excluding the Pledged Shares, the actual tradable shares were 662 million, accounting for 54.49% of the total share capital.
As soon as the ban was lifted, the two major shareholders of Shenzhen Ruilong and Shenzhen Ruifu couldn’t wait to start reducing their holdings. According to the third quarterly report of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) 2021, shareholders Shenzhen Ruilong and Shenzhen Ruifu held 47.3365 million shares and 45.1972 million shares respectively by the end of the third quarter of last year. However, by January 12, 2022, the number of shares held by them had decreased to 41.1417 million shares and 38.9532 million shares respectively, with a reduction of 6.1948 million shares and 6.244 million shares respectively. According to the stock price low of the above reduction range, the cash out amount of the two shareholders is at least 2 billion yuan, totaling more than 4 billion yuan.
In addition to the above two newly lifted shareholders, the previously lifted shareholders Shenzhen Ruijia and Shenzhen Ruixiang also reduced their holdings of hundreds of thousands to more than one million shares respectively, with a total cash out amount of more than 500 million yuan.
According to public data, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (hereinafter referred to as Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) ), as one of China’s “mechanical giants”, is mainly engaged in the R & D, manufacturing, marketing and service of medical devices. Its main products cover three fields, namely life information and support, in vitro diagnosis and medical imaging, including monitors, defibrillators, ultrasonic diagnostic systems, coagulation analyzers and so on.
In the third quarter of 2021, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) achieved steady growth in performance. Its revenue reached 6.613 billion yuan, a year-on-year increase of 20.25%, and its net profit was 2.318 billion yuan, a year-on-year increase of 21.42%. However, compared with 42.15% of the growth rate of net profit in 2020, it is almost halved, and the pressure on performance growth seems to be clearly visible.
At present, in terms of the latest secondary market of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , its share price was still 502 yuan / share in July 2021. As of today’s closing, its share price has fallen to 296.50 yuan / share, of which the market value has evaporated to 249.5 billion yuan.
